Faculty of Medicine
Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/14
Browse
95 results
Search Results
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Molecular Monitoring in Acute Myeloid Leukemia Patients Undergoing Matched Unrelated Donor - Hematopoietic Stem Cell Transplantation: Single Center Experience(Macedonian Academy of Sciences and Arts/Walter de Gruyter GmbH, 2020-12-08); ; ; Minimal residual disease (MRD) assessment in acute myeloid leukemia (AML) cases is a complex, multi-modality process and, though much of its clinical implications at different points are extensively studied, it remains even now a challenging area. It is a disease the biology of which governs the modality of MRD assessment; in patients harboring specific molecular targets, high sensitivity techniques can be applied. On the other hand, relapse is considered as the leading cause of treatment failure in AML patients undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT). - Some of the metrics are blocked by yourconsent settings
Item type:Publication, INEFFECTIVE ERYTHROPOIESIS IN PATIENT WITH BETA THALASSEMIA AND MYELODYSPLASTIC SYNDROME CASE REPORT(Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 2024); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, DISTINCT SUBGROUP OF PATIENTS WITH UNMUTATED IGHV1-69 CHRONIC LYMPHOCYTIC LEUKEMIA AFFECTED WITH COVID19 INFECTION - SINGLE CENTER EXPERIENCE(Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 2025); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, FIRST-LINE IMMUNOCHEMOTHERAPY FOR FOLLICULAR LYMPHOMA PATIENTS- SINGLE CENTER EXPERIENCE(Macedonian Association of Anatomists, 2024); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Haploidentical Stem Cell Transplantation in Patients with Myelodysplastic Syndrome: Case Report First Experience(Scientific Foundation Spiroski (publications), 2021-11-23); ; ; ; Popova Labachevska, MarijaBACKGROUND: Allogeneic stem cell transplantation (ASCT) is a potentially curative therapeutic approach in patients with intermediate and high-risk myelodysplastic syndrome (MDS). If a family sibling or unrelated donor is not available mismatched donors are viable option for young patients with no comorbidities. The aim of this case presentation was to evaluate our first experience with haploidentical transplantation for this indication. CASE PRESENTATION: We present a case of 50 years male patient with myelodysplastic syndrome (MDS) diagnosed at University Clinic for hematology, Skopje, North Macedonia. Patient was scored in IPSS -R as high risk patient. He was referred for HLA DNA typing of family siblings and since he didn’t have identical sibling and unrelated donor, he was referred to continue treatment with haploidentical stem cell transplantation. He received Flu Bu conditioning and PTCY, cyclosporine and MMF for GVHD prophylaxis. Peripheral blood stem cells (PBSC) from his mismatched brother were infused in the amount of CD34=5.8x106/kg. He experienced prolonged engraftment, severe infective bacterial infections and CMV reactivation with clinical manifestation of CMV colitis. He was successfully treated with antiviral drug and completely resolved. His bone marrow analysis showed complete remission and chimerism evaluation revealed high donor engraftment. Patient is now +34 months post transplant in complete remission. CONCLUSION: The use of a mismatched donor increases the risk of NRM, but there is also evidence to suggest that an haploidentical donor is a valid choice, as general outcome appears to be at least similar to MUD. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Special Conditions in Venous Thrombembolism - Case Series(Macedonian Academy of Sciences and Arts/Walter de Gruyter GmbH, 2019-10-01); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Special Conditions in Venous Thrombembolism – Case Series(Macedonian Academy of Sciences and Arts, 2019-10-01); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Long-Term Efficacy of Treatment in Elderly Patients With Hodgkin Lymphoma: A Retrospective Analysis(Elsevier BV, 2024-09); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Health-Related Quality of Life in Macedonian Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: EQ-5D-5L Assessment(Elsevier BV, 2024-09); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Effectiveness of Ropeginterferon Alfa-2B in High-Risk Patients with Philadelphia Chromosome Negative Myeloproliferative Neoplasms- Evaluation of Clinicohaematologic Response, and Safety Profile: Single Centre Experience(Македонска академија на науките и уметностите, Одделение за медицински науки = Macedonian Academy of Sciences and Arts, Section of Medical Sciences/Walter de Gruyter GmbH, 2023-12-01); ; ; Stojanovska-Jakimovska, SimonaBackground: Treatment of Philadelphia chromosome negative myeloproliferative neoplasms (Ph - MPNs) requires individualized approach depending on multiple factors. Novel pegylated Interferon (IFN) formulations have become an attractive therapeutic option in young Ph- MPN patients associated with better patient compliance. Methods: In this retrospective observational study a total of 16 high-risk Ph- MPN patients treated off-label with ropeginterferon alfa-2b given twice monthly, were included. Median follow-up was 24 months. High-risk patients were defined using the IPSET score. Response to treatment was evaluated using ELN, IWG-MET EUMNET standardized criteria and occurrence of side effects was documented. Results: 11 patients were female (68.8%) and 5 male (31.2%); average age at diagnosis was 36 years (17-51); 12 patients (75%) had ET, one (6.2%) PV and three (18.8%) hypercellular phase of PMF. JAK2V617F mutation was detected in 10 patients (62.5%), CALR in three (18.8%), and three (18.7%) were triple-negative cases. In 7 patients (43.7%), ropeginterferon alfa-2b was used in first-line, and 9 (56.3%) were previously treated with HU and/or standard IFN. Among initially ropeginterferon alfa-2b treated patients, complete haematological response was observed in 4/7 (57.1%), partial in 2/7 (28.6%) and suboptimal in one (14.3%). Complete haematological response was observed in 8/9 (88.9%) among previously treated patients. Average time to blood count normalization was 8 weeks, at a dose ranging between 100mcg and 300mcg. Side effects were observed in one patient (6.2%). Conclusion: Our experience is in support of previous studies regarding ropeginterferon alfa-2b efficacy and safety profile in the treatment of young patients with Ph- MPNs.